Dr. Noon CVD
1 paper3 findings
- Humans1
Effects
2Risk reclassification
upin humans1
1 study
Risk reclassification
upin humans1
Dr. Noon CVD improves risk reclassification in humans (NRI 0.484, 95% CI 0.233–0.666).
Humansadded to clinical model10-yearn = 7,832
Clinical hypertension1 Sep 2026
Discrimination
upin humans1
1 study
Discrimination
upin humans1
Dr. Noon CVD improves discrimination in humans (ΔC-index 0.030).
Humansadded to clinical model10-yearn = 7,832
Clinical hypertension1 Sep 2026
Associations
1Atherosclerotic cardiovascular mortality
upin humans1
1 study
Atherosclerotic cardiovascular mortality
upin humans1
Dr. Noon CVD predicts atherosclerotic cardiovascular mortality in humans (HR trend 1.49, 95% CI 1.21–1.85).
Humansadjusted for traditional factors and CKD10-yearn = 7,832
Clinical hypertension1 Sep 2026
Latest
4 in 12 monthsClinical Hypertension
Deep learning-based retinal risk stratification for 10-year atherosclerotic cardiovascular mortality in patients with hypertension and diabetes: a retrospective cohort study
Cohort study of 7,832 peopleBiomarkers
ADA Scientific Sessions 2026 Abstract
Longitudinal Validation of a Retinal AI Score for Cardiovascular Risk Monitoring: Validation in Korean and UK Populations
Study in peopleBiomarkers
ADA Scientific Sessions 2026 Abstract
Comparative Performance of a Retinal Imaging–Derived Biomarker and Traditional ASCVD Risk Scores in a Diabetic Cohort from a Community Endocrine Practice in Long Island City, New York
Study in peopleBiomarkers
ADA Scientific Sessions 2026 Abstract
Integrating Lipoprotein(a) with Retinal Imaging Biomarkers for Cardiovascular Risk Assessment: UK Biobank Analysis
Study in peopleBiomarkers
ADA Scientific Sessions 2025 Abstract
Enhancing Cardiovascular Disease (CVD) Risk Prediction Using Metabolic Profiling in the UK Biobank—Pooled Cohort Equations vs. Retinal Imaging Based Dr. Noon CVD
Study in peopleBiomarkers